LaunchPad Medical Rebrands as RevBio and Launches an Updated Website

"Many research partners, investors, and commercial partners felt that our prior name did not adequately express the transformational nature of our Tetranite technology platform," said Brian Hess, CEO of RevBio, Inc.  "We believe this new brand will now cast the right light on both the company and its products." "Many research partners, investors, and commercial partners felt that our prior name did not adequately express the transformational nature of our Tetranite technology platform," said...
LOWELL, Mass., (informazione.it - comunicati stampa - salute e benessere)

"Many research partners, investors, and commercial partners felt that our prior name did not adequately express the transformational nature of our Tetranite technology platform," said Brian Hess, CEO of RevBio, Inc.  "We believe this new brand will now cast the right light on both the company and its products."

As part of the company's rebranding activities it has also launched a new website (www.revbio.com) with detailed information on the markets it is seeking to enter and the status of its products that are currently under development.  Michael Tiedemann, Principal and Executive Creative Director at M! Brand Consulting, played an instrumental role in the development of the company's new brand and marketing materials.  "RevBio is poised to unleash a novel bioactive technology across multiple human and veterinary applications," said Tiedemann.  "It was critical that the new brand identity convey the extraordinary nature of this technology and the company dedicated to developing it."

About RevBio

LaunchPad Medical Rebrands as RevBio and Launches an Updated Website

Previously known as LaunchPad Medical, RevBio is a clinical stage medical device company engaged in the development and commercialization of a patented, synthetic, injectable, self-setting, and osteoconductive bone adhesive biomaterial called Tetranite®.  The company is initially developing this technology for use in the dental market, and recently initiated two clinical studies for the use of Tetranite to immediately stabilize dental implants placed in sites that lack sufficient primary stability.  The company is also working to develop adhesive applications for the broader orthopedics market.  RevBio's Tetranite technology is not yet approved for commercial use.

Logo - https://mma.prnewswire.com/media/1223702/RevBio.jpg

 

Per maggiori informazioni
Ufficio Stampa
 PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom
Allegati
Slide ShowSlide Show
Non disponibili